ID   UoC-B1
AC   CVCL_A296
SY   UOC-B1; UOCB1; UoCB1
DR   ChEMBL-Cells; CHEMBL4513110
DR   ChEMBL-Targets; CHEMBL4513133
DR   Cosmic; 1524827
DR   GEO; GSM236810
DR   GEO; GSM236846
DR   GEO; GSM3145744
DR   IARC_TP53; 28429
DR   PubChem_Cell_line; CVCL_A296
DR   Wikidata; Q54991245
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=7630190;
RX   PubMed=7849311;
RX   PubMed=7888679;
RX   PubMed=8164688;
RX   PubMed=8231254;
RX   PubMed=8704231;
RX   PubMed=9108419;
RX   PubMed=9823951;
RX   PubMed=20147975;
RX   PubMed=20519628;
RX   PubMed=20575032;
RX   PubMed=29786757;
RX   PubMed=35124168;
CC   Population: Caucasian.
CC   Sequence variation: Gene fusion; HGNC; 4977; HLF + HGNC; 11633; TCF3; Name(s)=TCF3-HLF, E2A-HLF (PubMed=8164688).
CC   Sequence variation: Mutation; HGNC; 7978; NR3C1; Simple; p.Cys477_Arg478insGlyLeuGly (c.1431_1432insGGTCTGGGC); Zygosity=Heterozygous (PubMed=35124168).
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
DI   NCIt; C9140; Childhood B acute lymphoblastic leukemia
DI   ORDO; Orphanet_99860; Precursor B-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   15Y6M
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 30-01-24; Version: 19
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=7630190;
RA   Zhou M.-X., Gu L.-B., James C.D., He J., Yeager A.M., Smith S.D.,
RA   Findley H.W.;
RT   "Homozygous deletions of the CDKN2 (MTS1/p16ink4) gene in cell lines
RT   established from children with acute lymphoblastic leukemia.";
RL   Leukemia 9:1159-1161(1995).
//
RX   PubMed=7849311; DOI=10.1182/blood.V85.4.893.bloodjournal854893;
RA   Stranks G., Height S.E., Mitchell P., Jadayel D.M., Yuille M.A.R.,
RA   De Lord C., Clutterbuck R.D., Treleaven J.G., Powles R.L.,
RA   Nacheva E., Oscier D.G., Karpas A., Lenoir G.M., Smith S.D.,
RA   Millar J.L., Catovsky D., Dyer M.J.S.;
RT   "Deletions and rearrangement of CDKN2 in lymphoid malignancy.";
RL   Blood 85:893-901(1995).
//
RX   PubMed=7888679; DOI=10.1182/blood.V85.6.1608.bloodjournal8561608;
RA   Zhou M.-X., Yeager A.M., Smith S.D., Findley H.W.;
RT   "Overexpression of the MDM2 gene by childhood acute lymphoblastic
RT   leukemia cells expressing the wild-type p53 gene.";
RL   Blood 85:1608-1614(1995).
//
RX   PubMed=8164688; DOI=10.1128/mcb.14.5.3403-3413.1994;
RA   Inaba T., Shapiro L.H., Funabiki T., Sinclair A.E., Jones B.G.,
RA   Ashmun R.A., Look A.T.;
RT   "DNA-binding specificity and trans-activating potential of the
RT   leukemia-associated E2A-hepatic leukemia factor fusion protein.";
RL   Mol. Cell. Biol. 14:3403-3413(1994).
//
RX   PubMed=8231254;
RA   Zhang L.Q., Downie P.A., Goodell W.R., McCabe N.R., Le Beau M.M.,
RA   Morgan R., Sklar J., Raimondi S.C., Miley D., Goldberg A., Lu M.-M.,
RA   Montag A., Smith S.D.;
RT   "Establishment of cell lines from B-cell precursor acute lymphoblastic
RT   leukemia.";
RL   Leukemia 7:1865-1874(1993).
//
RX   PubMed=8704231; DOI=10.1182/blood.V88.3.785.785;
RA   Kim D.-H., Moldwin R.L., Vignon C., Bohlander S.K., Suto Y.,
RA   Giordano L., Gupta R., Fears S., Nucifora G., Rowley J.D., Smith S.D.;
RT   "TEL-AML1 translocations with TEL and CDKN2 inactivation in acute
RT   lymphoblastic leukemia cell lines.";
RL   Blood 88:785-794(1996).
//
RX   PubMed=9108419; DOI=10.1182/blood.V89.8.2986;
RA   Findley H.W., Gu L.-B., Yeager A.M., Zhou M.-X.;
RT   "Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with
RT   p53 status and sensitivity to apoptosis in childhood acute
RT   lymphoblastic leukemia.";
RL   Blood 89:2986-2993(1997).
//
RX   PubMed=9823951; DOI=10.1038/sj.leu.2401198;
RA   Zhou M.-X., Gu L.-B., Yeager A.M., Findley H.W.;
RT   "Sensitivity to Fas-mediated apoptosis in pediatric acute
RT   lymphoblastic leukemia is associated with a mutant p53 phenotype and
RT   absence of Bcl-2 expression.";
RL   Leukemia 12:1756-1763(1998).
//
RX   PubMed=20147975; DOI=10.1038/leu.2010.8;
RA   Akahane K., Inukai T., Inaba T., Kurosawa H., Look A.T., Kiyokawa N.,
RA   Fujimoto J., Goto H., Endo M., Zhang X., Hirose K., Kuroda I.,
RA   Honna H., Kagami K., Goi K., Nakazawa S., Sugita K.;
RT   "Specific induction of CD33 expression by E2A-HLF: the first evidence
RT   for aberrant myeloid antigen expression in ALL by a fusion
RT   transcription factor.";
RL   Leukemia 24:865-869(2010).
//
RX   PubMed=20519628; DOI=10.1182/blood-2009-09-244673;
RA   Hirose K., Inukai T., Kikuchi J., Furukawa Y., Ikawa T., Kawamoto H.,
RA   Oram S.H., Gottgens B., Kiyokawa N., Miyagawa Y., Okita H.,
RA   Akahane K., Zhang X.-C., Kuroda I., Honna H., Kagami K., Goi K.,
RA   Kurosawa H., Look A.T., Matsui H., Inaba T., Sugita K.;
RT   "Aberrant induction of LMO2 by the E2A-HLF chimeric transcription
RT   factor and its implication in leukemogenesis of B-precursor ALL with
RT   t(17;19).";
RL   Blood 116:962-970(2010).
//
RX   PubMed=20575032; DOI=10.1002/ajh.21738;
RA   Inukai T., Zhang X.-R., Kameyama T., Suzuki Y., Yoshikawa K., Kuroda I.,
RA   Nemoto A., Akahane K., Sato H., Goi K., Nakamoto K., Hamada J.-i.,
RA   Tada M., Moriuchi T., Sugita K.;
RT   "A specific linkage between the incidence of TP53 mutations and type
RT   of chromosomal translocations in B-precursor acute lymphoblastic
RT   leukemia cell lines.";
RL   Am. J. Hematol. 85:535-537(2010).
//
RX   PubMed=29786757; DOI=10.1007/s12185-018-2474-7;
RA   Tomoyasu C., Imamura T., Tomii T., Yano M., Asai D., Goto H.,
RA   Shimada A., Sanada M., Iwamoto S., Takita J., Minegishi M., Inukai T.,
RA   Sugita K., Hosoi H.;
RT   "Copy number abnormality of acute lymphoblastic leukemia cell lines
RT   based on their genetic subtypes.";
RL   Int. J. Hematol. 108:312-318(2018).
//
RX   PubMed=35124168; DOI=10.1016/j.jsbmb.2022.106068;
RA   Tamai M., Kasai S., Akahane K., Thu T.N., Kagami K., Komatsu C.,
RA   Abe M., Watanabe A., Goi K., Miyake K., Inaba T., Takita J., Goto H.,
RA   Minegishi M., Iwamoto S., Sugita K., Inukai T.;
RT   "Glucocorticoid receptor gene mutations confer glucocorticoid
RT   resistance in B-cell precursor acute lymphoblastic leukemia.";
RL   J. Steroid Biochem. Mol. Biol. 218:106068.1-106068.12(2022).
//